Pembrolizumab (Keytruda) is a targeted therapy against the programmed cell death-1 (PD-1) receptor. Occasionally it may be associated with development of Type 1 diabetes mellitus.
Risk factor: diabetes-prone HLA genotype
Clinical features:
(1) absence of diabetes prior to pembrolizumab therapy
(2) onset of hyperglycemia with ketoacidosis after starting pembrolizumab
(3) absence of an alternative explanation for the diabetes
